MedMesh.i
Curation
Accueil
Racine
Curation
Exploration
Accueil
Racine
Accueil

Serveur d'exploration sur les peptides biopesticides - Curation (Accueil)

Index « MedMesh.i » - entrée « Dermatologic Agents »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Dermatitis, Irritant < Dermatologic Agents < Dermatology  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 41.
[0-20] [0 - 20][0 - 41][20-40]
Ident.Authors (with country if any)Title
000243 (2019) S. D'Adamio [Italie] ; D. Silvaggio [Italie] ; P. Lombardo [Italie] ; L. Bianchi [Italie] ; M. Talamonti [Italie] ; M. Galluzzo [Italie]The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
000606 (2018) Brian Liu ; Robert A. Schwartz [États-Unis]Potential Cardio-protective Effects of Psoriasis Medications.
000653 (2018) Moeko Doi ; Yuki Sagawa ; Takumi Tanaka ; Taeko Mizutani ; Yuri Okano ; Hitoshi MasakiDefensive Effects of a Unique Polysaccharide, Sacran, to Protect Keratinocytes against Extracellular Stimuli and Its Possible Mechanism of Action.
000829 (2019) Seohee Deanne Choi [Australie] ; Mario I. D'Souza [Australie] ; Scott W. Menzies [Australie] ; Wolfgang Weninger [Australie]A prospective observational study of pigmented naevi changes in psoriasis patients on biologic therapy.
000943 (2018) K L Winthrop [États-Unis] ; X. Mariette [France] ; J T Silva [Espagne] ; E. Benamu [États-Unis] ; L H Calabrese [États-Unis] ; A. Dumusc [Suisse] ; J S Smolen [Autriche] ; J M Aguado [Espagne] ; M. Fernández-Ruiz [Espagne]ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
000B99 (2018) E. Peleva [Royaume-Uni] ; L S Exton [Royaume-Uni] ; K. Kelley [Royaume-Uni] ; C E Kleyn [Royaume-Uni] ; K J Mason [Royaume-Uni] ; C H Smith [Royaume-Uni]Risk of cancer in patients with psoriasis on biological therapies: a systematic review.
000C80 (2017) Selma Atalay [Pays-Bas] ; Juul M P A. Van Den Reek [Pays-Bas] ; Lieke J. Van Vugt [Pays-Bas] ; Marisol E. Otero [Pays-Bas] ; Peter C M. Van De Kerkhof [Pays-Bas] ; Alfons A. Den Broeder [Pays-Bas] ; Wietske Kievit [Pays-Bas] ; Elke M G J. De Jong [Pays-Bas]Tight controlled dose reduction of biologics in psoriasis patients with low disease activity: a randomized pragmatic non-inferiority trial.
000E24 (2017) Natasha Irrera [Italie] ; Mario Vaccaro [Italie] ; Alessandra Bitto [Italie] ; Giovanni Pallio ; Gabriele Pizzino ; Maria Lentini [Italie] ; Vincenzo Arcoraci ; Letteria Minutoli ; Michele Scuruchi ; Giuseppina Cutroneo ; Giuseppe Pio Anastasi [Italie] ; Roberta Ettari [Italie] ; Francesco Squadrito ; Domenica Altavilla [Italie]BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis.
000F27 (2017) A B Gottlieb [États-Unis] ; J-P Lacour [France] ; N. Korman [États-Unis] ; S. Wilhelm [Allemagne] ; Y. Dutronc [France] ; A. Schacht [Allemagne] ; J. Erickson [États-Unis] ; L. Zhang [États-Unis] ; L. Mallbris [États-Unis] ; S. Gerdes [Allemagne]Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies.
000F93 (2016) Monika Białecka [Pologne] ; Roksana Ostasz ; Mateusz Kurzawski ; Adam Klimowicz ; Honorata Fabia Czyk ; Piotr Bojko ; Violetta Dziedziejko ; Krzysztof Safranow ; Anna Machoy-Mokrzy Ska ; Marek Dro DzikIL17A and IL17F Gene Polymorphism Association with Psoriasis Risk and Response to Treatment in a Polish Population.
001030 (2016) R B Warren [Royaume-Uni] ; S C Weatherhead [Royaume-Uni] ; C H Smith [Royaume-Uni] ; L S Exton [Royaume-Uni] ; M F Mohd Mustapa [Royaume-Uni] ; B. Kirby [Irlande (pays)] ; P D Yesudian [Royaume-Uni]British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.
001063 (2016) E. Herédi [Hongrie] ; J. Végh [Hongrie] ; L. Pogácsás [Hongrie] ; K. Gáspár [Hongrie] ; J. Varga [Hongrie] ; G. Kincse [Hongrie] ; M. Zeher [Hongrie] ; A. Szegedi [Hongrie] ; J. Gaál [Hongrie]Subclinical cardiovascular disease and it's improvement after long-term TNF-α inhibitor therapy in severe psoriatic patients.
001483 (2015) Patricia Shu Kurizky [Brésil] ; Clarissa De Castro Ferreira [Brésil] ; Lucas Souza Carmo Nogueira [Brésil] ; Licia Maria Henrique Da Mota [Brésil]Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.
001490 (2015) Carolina Medina-Gil [États-Unis] ; Luis Dehesa [États-Unis] ; Adriane Vega [États-Unis] ; Francisco Kerdel [États-Unis]Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
001622 (2015) Guy Shalom [Israël] ; Devy Zisman [Israël] ; Haim Bitterman [Israël] ; Ilana Harman-Boehm [Israël] ; Sari Greenberg-Dotan [Israël] ; Jacob Dreiher [Israël] ; Ilan Feldhamer [Israël] ; Hadas Moser [Israël] ; Ariel Hammerman [Israël] ; Yoram Cohen [Israël] ; Arnon D. CohenSystemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
001678 (2015) Dagmar Wilsmann-Theis [Allemagne] ; Yvonne Frambach ; Sandra Philipp ; Ansgar J. Weyergraf ; Arnd Jacobi ; Rotraut Mössner ; Sascha GerdesSystemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases.
001770 (2015) Jordi Esquirol Caussa [Espagne] ; Elisabeth Herrero Vila [Espagne][Epidermal growth factor, innovation and safety].
001A25 (2014) Esther De Eusebio [Espagne] ; José Carlos Armario-Hita ; Víctor Alegre De MiquelTreatment of psoriasis: focus on clinic-based management with infliximab.
001A65 (2014) Nawaf Al-Mutairi [Éthiopie] ; Tarek NourThe effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
001C66 (2013) Gillian M. Heinecke ; Adam J. Luber ; Jacob O. Levitt ; Mark G. LebwohlCombination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
001C89 (2013) Evren Odyakmaz Demirsoy ; Rebiay K Ran ; Selma Salman ; Ci Dem Ca Layan ; Aysun Sikar Aktürk ; Dilek Bayramgurler ; Nilgün BilenEffectiveness of systemic treatment agents on psoriatic nails: a comparative study.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/MedMesh.i -k "Dermatologic Agents" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/MedMesh.i  \
                -Sk "Dermatologic Agents" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    BiopestPeptidV1
   |flux=    Main
   |étape=   Curation
   |type=    indexItem
   |index=    MedMesh.i
   |clé=    Dermatologic Agents
}}
Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 19:22:35 2020. Site generation: Thu Nov 19 19:33:26 2020